
BNTC Stock Forecast & Price Target
BNTC Analyst Ratings
Bulls say
Benitec Biopharma Inc is positioned for optimistic growth due to its innovative silent and replace-based therapeutics for Oculopharyngeal Muscular Dystrophy (OPMD), showing promising initial results that could lead to expedited regulatory interactions and potential accelerated approvals. The interim data from the increased patient cohort reflects a 100% responder rate, with sustained improvements in critical swallowing metrics, suggesting a significant therapeutic impact, which may enable premium pricing strategies. Additionally, long-term data indicates a trend of progressive improvement over time, enhancing the overall probability of obtaining market approval and reinforcing the company's strong growth potential in the biotechnology sector.
Bears say
Benitec Biopharma Inc. reported a net loss of $0.21 per share in F1Q26, which was better than the forecasted loss of $0.41 per share, primarily due to a higher-than-anticipated weighted average number of shares outstanding. However, the company faces significant risks, including potential delays or failures in obtaining regulatory approval for its flagship product BB-301, which could adversely affect the company’s stock price. Additionally, the ongoing clinical trial's slower-than-expected progress and the possibility of negative data or unexpected side effects further contribute to a negative outlook, compounded by concerns regarding long-term equity dilution.
This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
BNTC Analyst Forecast & Price Prediction
Start investing in BNTC
Order type
Buy in
Order amount
Est. shares
0 shares